Bladder Cancer Perspective

• S2 Episode 3: Personalized Medicine in Bladder Cancer: Inflection Point   Drs Cheryl Lee and Tom Powles talk about ctDNA and personalized medicine approaches for advanced bladder cancer as we sit at the precipice of change.
  Medscape, May 23, 2023
• AUA 2023 Read clinically focused news coverage of key developments from AUA 2023
  Medscape Urology, April 28, 2023
• S2 Episode 2: How Bladder Cancer Immunostimulant N-803 May Shake Things Up   Drs Cheryl Lee and Karim Chamie talk about efforts to develop nogapendekin alfa, aka N-803, and where it may fit into the shifting treatment paradigm for non–muscle-invasive bladder cancer.
  Medscape, April 20, 2023
• S2 Episode 1: Breaking Bladder Cancer Barriers: Promise of Gene Therapy   Drs Cheryl Lee and Stephen Boorjian share detailed insights about a model drug development partnership involving the first-in-class therapy for BCG-unresponsive non–muscle-invasive bladder cancer.
  Medscape, April 20, 2023
• EAU 2023 Read clinically focused news coverage of key developments from EAU 2023
  Medscape Urology, March 08, 2023
• GUCS 2023 Read clinically focused news coverage of key developments from GUCS 2023
  Medscape Oncology, February 15, 2023
• More Guidance Needed for Cancer Screening in Rheumatology Karmela Kim Chan, MD, discusses new myositis cancer screening guidelines as a good starting point for future needed efforts to guide cancer screening in patients with rheumatic diseases.
  Hospital for Special Surgery, January 12, 2023
• S1 Episode 5: Biomarkers and Renal Cell Carcinoma   Drs Sumanta Pal and Rana McKay discuss the use of biomarkers in treating patients with renal cell carcinoma to identify whose disease will recur and who will respond to therapy.
  Medscape, December 08, 2022
• S1 Episode 6: Non-Muscle Invasive Bladder Cancer Innovations   Drs Cheryl Lee and Sima Porten discuss urinary biomarkers, enhanced cystoscopy, treatments on the horizon, and communication with team members from the cytopathology lab using PARIS classification.
  Medscape, November 08, 2022
• S1 Episode 5: Bladder Cancer Advances Abound, but for Which Patients?   Drs Cheryl Lee and Angela Smith discuss bladder cancer research focused on disparities in healthcare affecting women and minorities.
  Medscape, October 06, 2022
• State of the Art in NAFLD/NASH Identification and Management   Drs Seth Baum and Jay Shubrook explore the highly anticipated Clinical Care Pathway for the screening, diagnosis, and treatment of NAFLD/NASH.
  American College of Cardiology & Medscape , October 03, 2022
• S1 Episode 4: Key Advances in Radiation Therapy for Bladder Cancer   Drs Cheryl Lee and Sophia Kamran discuss the exciting and evolving role of radiation therapy in treating bladder cancer.
  Medscape, September 08, 2022
• Bladder Cancer e-Tumor Boards: Case 3: Metastatic Bladder Cancer   This case focuses on a 67-year-old man who is diagnosed with metastatic urothelial carcinoma with liver mets. The MSK team discusses treatment plans and switching treatments when the patient no longer responds.
  Medscape, August 11, 2022
• S1 Episode 3: How Can ctDNA Testing Improve Bladder Cancer Care?   Drs Cheryl Lee and Peter Black share exciting new ways to use liquid biopsy ctDNA testing for bladder cancer diagnostics and patient monitoring.
  Medscape, August 10, 2022
• S1 Episode 2: How to Optimize Treatment Timing in Bladder Cancer   Drs Cheryl Lee and Matthew Galsky superbly synthesize the latest critical elements for sequencing perioperative bladder cancer therapies.
  Medscape, July 06, 2022
• S1 Episode 1: Bladder Cancer Choices: Robotic or Open Cystectomy?   Bladder cancer surgeons Drs Cheryl Lee and Khurshid Guru are inspired by a recent Swedish study and discuss aggregate surgical outcomes data comparing their own different approaches.
  Medscape, July 06, 2022
• EAU 2022 Read clinically focused news coverage of key developments from EAU 2022
  Medscape Urology, July 01, 2022
• ASCO 2022: A Reflection on Data to Build On in Bladder Cancer   Cheryl Lee, MD, considers the updates on several studies presented at ASCO 2022.
  Medscape, June 30, 2022
• Key Studies in Bladder Cancer From ASCO 2022   Key studies in bladder cancer from ASCO 2022 cover switch maintenance, analysis of the JAVELIN Bladder 100, and criteria defining "platinum ineligible" patients, as discussed by Dr Petros Grivas.
  Medscape, June 29, 2022
• ASCO 2022: Data for Better Decision-Making in the Treatment of Advanced Bladder Cancer   Tracy L. Rose, MD, MPH, discusses the immediate impact that study data from the 2022 ASCO annual meeting bladder cancer poster sessions will have on treatment decisions facing providers and patients.
  Medscape, June 27, 2022